Akebia Receives European Commission Approval for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance DialysisPRNewsWire • 04/25/23
Akebia Therapeutics to Host Stockholder Information Session to Discuss Rationale for Reverse Stock SplitPRNewsWire • 04/14/23
Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2023PRNewsWire • 04/07/23
Akebia Therapeutics Announces Positive Top-Line Results from Vadadustat Alternative Dosing StudyPRNewsWire • 04/03/23
Akebia Therapeutics Files Revised Definitive Proxy Statement for Special Stockholder MeetingPRNewsWire • 03/24/23
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/09/23
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business HighlightsPRNewsWire • 03/09/23
Akebia Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Discuss Recent Business HighlightsPRNewsWire • 03/02/23
Akebia Receives Positive CHMP Opinion in Europe for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance DialysisPRNewsWire • 02/23/23
Akebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney DiseasePRNewsWire • 02/21/23
Akebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDAPRNewsWire • 12/22/22